Overview of Hidrasec Children

Property	Description
Active ingredient	Racecadotril
Form	Granules for oral suspension (powder sachets)
Pharmacological class	Selective Enkephalinase Inhibitor
General purpose	Symptomatic relief of acute watery diarrhea
Origin	Synthetic organic prodrug

What Type of Medicine is Hidrasec Children?

Hidrasec Children is a specific, brand-name pharmaceutical preparation classified as an antidiarrheal agent intended primarily for children and infants over three months of age. This formulation contains the single active ingredient, Racecadotril, and belongs to the unique pharmacological class of Selective Enkephalinase Inhibitors (or Neutral Endopeptidase Inhibitors). The medicine functions as a purely antisecretory agent, which distinguishes its mechanism from older motility-slowing compounds.

This distinction is clinically recognized, as this antisecretory approach avoids interference with the gut's natural muscular contractions. Hidrasec Children is designed specifically to target the underlying hypersecretion of water and electrolytes, providing symptomatic relief without affecting normal bowel motility, a key differentiating factor in pediatric care.

Composition, Form, and Origin

The active ingredient, Racecadotril, is a synthetic organic compound produced through chemical synthesis. It functions as a prodrug, which the body rapidly converts into the active metabolite, Thiorphan, upon administration. A crucial feature of the Hidrasec Children brand is its specialized dosage form—granules for oral suspension packaged in individual powder sachets.

This form addresses the specific needs of its target audience by allowing the product, which uses a solid oral dispersion base/vehicle of pharmaceutical excipients, to be mixed easily into water or soft food for the oral route of administration. As a single active ingredient product, its composition focuses the therapeutic effect solely on the targeted enkephalinase inhibitor mechanism.

General Therapeutic Purpose

The overall therapeutic purpose of this medicine is to act as a Fluid Flow Regulator in the small intestine, providing rapid symptomatic relief from acute watery diarrhea. This effect is achieved because its mechanism provides protection of endogenous enkephalins, which are natural substances that help regulate fluid balance. Racecadotril acts to reduce intestinal hypersecretion, supporting a targeted approach to managing diarrhea symptoms.

By preserving the body's natural regulators, Hidrasec Children reduces the abnormal loss of water and salts without interfering with the gut's normal transit time. It is used as an adjuvant treatment (complementary therapy) that supports the essential practice of rehydration by minimizing fluid loss, making it a recognized tool in the management of acute pediatric diarrhea.

What side effects are possible with Hidrasec Children?

Possible Side Effects and Safety Information

The safety profile for Racecadotril, the active ingredient in Hidrasec Children, outlines adverse reactions categorized primarily by frequency and the body systems they affect, based on official regulatory documents.

Frequency-Classified Adverse Reactions

Adverse effects are formally grouped by regulatory authorities:

Common (reported in 1 to 10 users out of 100): Headache.
Uncommon (reported in 1 to 10 users out of 1,000): Rash, Erythema (skin redness), and Tonsillitis (observed in the pediatric population).
Frequency Not Known: This category is used for reactions identified primarily through post-marketing surveillance, where the exact rate of occurrence cannot be estimated. It includes severe cutaneous adverse reactions (SCARs), such as Angioedema and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), as well as Urticaria (hives).

Most documented effects fall under Skin and subcutaneous tissue disorders and Nervous system disorders.

Safety-Related Restrictions and Considerations

Official prescribing information includes specific limitations regarding the use of this medicine:

Prior Hypersensitivity and Underlying Conditions: The medicine is contraindicated in cases of known hypersensitivity to the active substance or excipients. Due to excipient content, use is restricted in patients with rare hereditary problems of sugar intolerance, such as fructose intolerance or glucose-galactose malabsorption.
Concurrent Symptoms: Racecadotril is not recommended for administration when bloody or purulent stools and fever are present, as these symptoms may indicate a severe or invasive bacterial infection.
Special Populations: Use is not recommended for infants under three months of age due to a lack of specific clinical trial data in this population. Caution is advised for patients with renal or hepatic impairment due to limited safety data.
Interaction Safety: Concomitant use with ACE inhibitors (a class of blood pressure medicines) is documented to carry an augmented risk of developing bradykinin-mediated angioedema.

Overdose and Emergency Response

Overdose and When to Seek Help

The official information regarding the overdose profile for racecadotril, the active substance in Hidrasec Children, indicates that no cases of overdose have been reported in children.

Data from adults suggests a high margin of safety: in sporadic cases, single doses up to 2 grams (which is equivalent to 20 times the therapeutic adult dose) were administered without any described harmful effects.

Due to the lack of reported overdose events, no specific symptoms or clinical manifestations associated with excessive intake are documented in regulatory sources for the paediatric population. Management of a suspected overdose should follow recognised clinical procedures for acute intoxication, as no specific antidote has been identified.

Immediate Medical Attention

While high single-dose exposure has not been associated with harm, immediate medical attention is necessary if a child exhibits signs of a severe allergic reaction (angioedema). Symptoms that require prompt emergency therapy include swelling of the face, tongue, glottis, and/or larynx, particularly if associated with difficulty breathing or swallowing. This reaction is a severe side effect, distinct from overdose, and requires immediate and close medical supervision.

Therapeutic Uses of Hidrasec Children

What Hidrasec Children Treats: Main Uses and Benefits

The primary therapeutic role of Hidrasec Children is to provide focused symptomatic relief within specific domains of acute diarrhea, supporting pediatric patients during challenging episodes. This medicine is commonly used as a complementary symptomatic treatment for acute diarrhea in infants and children. The treatment is relevant for easing symptoms linked to organ-specific functional stress, such as those associated with gastroenteritis.

Symptomatic Support and Fluid Balance

The medicine is applied in addressing the symptom cluster of excessive frequency and volume of watery stools, which contributes to easing discomfort during periods of heightened symptoms. It is considered relevant in contexts where symptoms create a significant physiological strain and assists with managing the noticeable functional strain, providing supportive relief for symptoms related to systemic imbalance. The overall benefit supports patients during difficult episodes by easing distress and may help maintain a sense of stability when symptoms are more noticeable.

This treatment is commonly applied as a complementary therapy alongside the essential use of Oral Rehydration Solutions (ORS), applied during phases of increased distress or discomfort when symptoms become temporarily overwhelming.

Quick Fact: Relief for Watery Stools
Used for managing: Symptoms related to heightened physiological activity, specifically excessive fluid output and systemic imbalance in children.

Regulatory References

Scottish Medicines Consortium advice

Eligibility and Restrictions for Use

Populations Permitted and Prohibited from Use

Hidrasec Children (racecadotril) is officially indicated for use in infants older than three months and children. The eligibility profile is strictly governed by contraindications and limitations defined by regulatory authorities.

Eligibility Status	Patient Population
Allowed	Infants ge 3 months and children.
Contraindicated	Known hypersensitivity to racecadotril or excipients, and hereditary disorders like fructose intolerance or glucose-galactose malabsorption.

Regulatory Limitations on Use

Official labeling specifies critical limitations on who should not receive the medicine:

Organ Function Exclusion: Use is strictly prohibited in children with existing renal impairment or hepatic impairment due to a lack of clinical studies in these populations.
Symptom Exclusion: The medicine must not be administered when diarrhea presents with fever and bloody or purulent stools.
Not Recommended Groups: Use is not recommended for infants under three months old, chronic diarrhea, or antibiotic-associated diarrhea.
Reproductive Status: The medicine should not be administered to women who are pregnant or breastfeeding because specific safety data for these populations is insufficient.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Racecadotril, the active ingredient in Hidrasec Children, establishes specific constraints related to pharmacodynamic effects while confirming a low potential for metabolic drug-drug interactions.

Documented Interaction Patterns

Interaction Type	Specific Constraint/Finding
Pharmacodynamic Risk	Concomitant use with Angiotensin-Converting Enzyme (ACE) Inhibitors (e.g., enalapril, ramipril) is not recommended due to a potential increase in the risk of bradykinin-mediated angioedema.
	This non-recommended status extends to other medicinal products known to cause bradykinin-mediated angioedema, such as certain Angiotensin II antagonists and mTOR inhibitors.
Metabolic Potential	Racecadotril and its active metabolite are documented as not having clinically relevant effects as inhibitors or inducers of major CYP enzymes (e.g., CYP3A4, 2D6), indicating a low potential for pharmacokinetic interference.
Co-Administered Drugs	Clinical studies documented no modification of drug kinetics when co-administered with other agents like Loperamide or Nifuroxazide.
Food Constraint	The presence of food delays the time to peak plasma concentration (Tmax), but does not affect the total bioavailability (AUC) of the active substance.

Population-Specific Notes

The medicine is not recommended for use in patients with any degree of renal impairment or hepatic impairment. This caution is noted in regulatory labeling due to an explicit lack of specific clinical and interaction information in these populations.

Mechanism of Action

The mechanism of action involves a targeted, peripheral effect that influences fluid and electrolyte transport in the small intestine. The process is defined by selective enzyme inhibition, resulting in the modification of a physiological secretory process.

Targeted Inhibition of Enkephalinase

The administered prodrug, Racecadotril, is rapidly converted into the active metabolite, Thiorphan, which functions as a selective inhibitor of the enzyme Neutral Endopeptidase (NEP), also known as Enkephalinase. This enzyme is situated on the brush border of intestinal epithelial cells. By blocking NEP, the mechanism causes a local increase in the concentration of endogenous fluid-regulating peptides, the enkephalins, by preventing their enzymatic breakdown. This action modulates an existing regulatory system by acting upon an endogenous enzyme.

Modification of Intestinal Secretory Pathways

The resultant enhanced signaling of enkephalins leads to increased activation of the delta (delta) opioid receptors on the enterocytes. This receptor engagement triggers an intracellular cascade that results in the reduction of the signaling molecule cyclic AMP (cAMP), which is the primary molecular driver of active ion and fluid secretion. This action results in the inhibition of excessive ion and fluid transport, which modifies the net fluid flux across the intestinal epithelium.

Maintenance of Normal Propulsive Activity

The mechanism exhibits high selectivity for the secretory process and does not interact significantly with the mu-opioid receptors responsible for gut muscle contraction. The active metabolite is confined to the peripheral nervous system and does not cross the blood-brain barrier. The mechanism's selectivity confines its action to the secretory process, which maintains the normal propulsive activity and transit time of the gastrointestinal tract.

Dosage and Administration Information

How to Use Hidrasec Children

Hidrasec Children (racecadotril) is administered exclusively via the oral route using granules for oral suspension. Its use is defined as a complementary symptomatic treatment alongside the mandatory use of Oral Rehydration Solutions (ORS). The medicine is approved for use in infants and children older than 3 months.

Official Dosing and Administration Schedule

Feature	Official Instruction
Dose Calculation	The standard dose is calculated based on the child's body weight: 1.5 mg per kilogram (1.5 mg/kg) per dose.
Frequency	Administration is three times daily (t.i.d.) at regular intervals.
First Day Procedure	A first dose is given immediately on day one, followed by a maximum of three total doses spread over the day.
Timing	Doses should preferably be administered at the beginning of the three main meals.

Preparation and Course Duration

Before administration, the contents of the sachet must be dispersed by mixing them thoroughly with water, soft food, or milk (e.g., in a feeding bottle) for immediate oral consumption.

Treatment must be continued until the child passes two normal stools. However, the total duration of use must not exceed seven days under any circumstances. There is currently insufficient data to recommend use in children with hepatic or renal impairment.

Procedural Summary

This protocol ensures a standardized administration based on prescribing information. The treatment sequence involves establishing the correct weight-based dosage, mixing the granules with food or liquid, and administering the dose three times daily in combination with necessary Oral Rehydration Solutions. The course is defined by symptom resolution and a fixed time limit.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Focus of Study Programs

Research programs evaluated study endpoints related to racecadotril and the body's digestive function. Studies assessed changes in reported stool output and frequency in children diagnosed with acute diarrhea. Clinical trials focused on assessing differences in hydration status and the duration of diarrhea episodes.

Evaluation of Symptom Changes Over Time

A number of clinical trials were conducted to compare various outcome measures between participants receiving racecadotril and those receiving placebo or standard care, often alongside rehydration therapy. Trial data indicated statistically significant differences in the average duration of diarrhea when comparing the group receiving racecadotril to control groups.

Additional studies explored measures related to the need for prolonged hospital admission and the volume of rehydration fluid required. Findings suggested a potentially reduced need for ongoing oral rehydration solution (ORS) intake in some study groups receiving the drug.

Safety and Tolerability Profile

The clinical trial data described the reported adverse events, which were frequently mild and temporary, primarily involving minor skin reactions. Data from clinical trials showed that the discontinuation rate attributed to adverse events was similar between the racecadotril and control groups.

Studies note that racecadotril is used as an adjunct treatment and does not replace the need for oral rehydration therapy in children.

Key Studies & References

European Society for Paediatric Gastroenterology Hepatology and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014

Frequently Asked Questions (FAQ)

Common questions about Hidrasec Children (FAQ)

Q: What's the main difference between Hidrasec Children and oral rehydration salts (ORS)?

According to official product information, Hidrasec Children is a pure intestinal anti-secretory substance. This means it works to reduce the excessive loss of water and electrolytes from the gut. Oral Rehydration Solution (ORS), on the other hand, is specifically for rehydration—it replaces the essential fluids and salts that the body has already lost. The medicine is an adjuvant treatment and is not intended to replace ORS.

Q: Is the medicine the only thing needed, or do I still need to give fluids?

Official regulatory documents emphasize that the use of this medicine is complementary. It is an adjuvant treatment that must be used alongside Oral Rehydration Solution (ORS). The administration of the medicine does not replace the requirement for continued use of fluids to maintain hydration, as the medicine does not contain electrolytes.

Q: Is it possible for Hidrasec Children to cause a skin rash?

Yes, regulatory documents list skin rash and erythema (skin redness) as Uncommon adverse reactions, meaning they are reported in 1 to 10 users out of 1,000. Certain severe skin reactions, including urticaria (hives), have also been reported in the post-marketing setting.

Q: Is it true that this medicine only works on a specific type of diarrhea?

The medicine is indicated for the symptomatic treatment of acute diarrhea. Official sources state that the medicine is not recommended for use when bloody or purulent stools and fever are present, as these symptoms may indicate a severe or invasive bacterial infection.

Q: Can a child with liver problems take this medicine?

Caution is advised for patients with hepatic impairment (liver problems). Official documents state the medicine is not recommended for use in this population due to a lack of specific clinical information from studies in patients with liver impairment.

Q: Does Hidrasec Children contain gluten, sugar, or artificial sweeteners?

Official documents indicate that the product contains sucrose (a sugar), and its use is restricted in patients with rare hereditary problems related to sugar intolerance, such as fructose intolerance. While the product contains sucrose, specific information regarding gluten or artificial sweeteners is not detailed in the official warnings section of the regulatory summaries.

Q: Is Hidrasec Children the same type of medicine as an antibiotic?

No. Official documents clarify that Hidrasec Children is a pure intestinal anti-secretory substance that reduces excessive fluid loss. It is not an antibiotic, meaning it does not fight bacteria, and it has not been tested in diarrhea associated with antibiotic use.

Q: Does Hidrasec Children stop diarrhea or just replace what's lost?

The medicine works as an anti-secretory substance. It decreases the intestinal hypersecretion of water and electrolytes, which reduces the amount of fluid lost from the body due to the diarrhea. It does not replace lost fluids; that is the role of Oral Rehydration Solution (ORS).

Q: Why is Hidrasec Children used for children and not adults?

The granules for oral suspension formulation of this medicine are specifically indicated for use in infants older than three months and children. Separate formulations, typically capsules with a higher strength, are licensed and prescribed for use in adults.

Q: How quickly does Hidrasec Children usually start to work?

According to official pharmacokinetic properties, the desired effect (enzyme inhibition) begins approximately 30 minutes after the medicine is taken. The maximum level of the enzyme inhibition is typically reached around two hours after administration.

Q: Can a child still eat regular food while taking Hidrasec Children?

Official documents state that taking the medicine with food does not change the total amount of the active substance absorbed by the body. However, food may delay the time at which the maximum anti-secretory effect is reached by about one and a half hours.

Q: What is the main active ingredient in Hidrasec Children?

The main active substance in the medicine is Racecadotril. This substance is administered as a prodrug, meaning it must be rapidly converted by the body into its active metabolite, Thiorphan, to produce its therapeutic effect.

Q: Does the powder have a specific taste?

Scientific studies on the medicine's formulation note that the active substance itself has an unpleasant taste. The pediatric granules are formulated using taste-masking components to help make the medicine palatable for children.

Q: What is the difference between the 10mg and 30mg presentations of Hidrasec?

The 10 mg and 30 mg sachets contain the same medicine but in different strengths. The specific presentation used is chosen based on the child's body weight to allow for accurate individual dosing.

Q: Does the package insert include a list of all inactive ingredients?

Yes. Official regulatory documents for the medicine, such as the Summary of Product Characteristics (SmPC), are required to list all excipients (inactive ingredients) in a section titled 'List of excipients'.

Q: Why is the drug described as a 'pro-drug' in medical information?

It is described as a prodrug because the substance, Racecadotril, is inactive when administered. It must be rapidly hydrolysed (broken down) by the body to form its active metabolite, Thiorphan, which is the substance that produces the intended anti-secretory effect.

Q: Is the purpose of Hidrasec Children to treat the cause of diarrhea or just the symptoms?

The product is officially indicated for the symptomatic treatment of acute diarrhea, meaning it targets the effect (fluid loss). If a treatment for the underlying cause is available, this medicine is used as a complementary treatment.

Q: How does the medicine affect the stool volume or consistency?

The anti-secretory mechanism of action reduces the excessive movement of ions and fluid in the small intestine. Clinical trials reported a reduction in the total stool output and volume in children with acute diarrhea who received the medicine.

Q: Can children with known heart conditions use this medicine?

Official documents do not list general heart conditions as a specific restriction. Studies have indicated that the active substance did not cause prolongation of the QTc interval (a measure of heart rhythm) in healthy volunteers.

Q: Is Hidrasec Children the official brand name in all countries where it is sold?

No. While Hidrasec is a common trade name for the product containing racecadotril, the medicine is sold under various other brand names, such as Tiorfan, in different countries around the world.

Q: Does Hidrasec Children cause constipation after the diarrhea stops?

The medicine’s mechanism of action does not modify the duration of intestinal transit. During clinical development, the rate of secondary constipation observed was comparable to the placebo group.

Q: Are there any common foods or drinks that make Hidrasec Children less effective?

Official documents state that the total amount of medicine absorbed by the body is not changed by food or drink. However, taking the medicine with food may delay the time at which the maximum anti-secretory effect is reached.

Q: Do studies suggest any long-term effects from using Hidrasec Children for short periods?

Official documentation does not provide information regarding long-term effects of the medicine. The total treatment duration is limited to a maximum of seven days, and use for chronic diarrhea has not been sufficiently studied.

Q: Does the regulatory approval specify a minimum weight for the child to use the medicine?

Yes. While the medicine is indicated for infants older than three months, some regulatory approvals for certain liquid formulations also specify a minimum weight of 7 kg and more for the child.

Q: Is Hidrasec Children considered an opioid or a stimulant?

The medicine is defined as a selective enkephalinase inhibitor. Its action is confined to the peripheral nervous system, and it is not a CNS stimulant or a traditional opioid with central effects.

Q: Is it normal for the diarrhea to stop immediately after taking Hidrasec Children?

The anti-secretory action begins approximately 30 minutes after taking the medicine, and the maximum effect is typically reached two hours after administration. While it is a rapid-acting drug, the duration of the treatment course is determined by the passage of two normal stools, not necessarily an immediate stop.

Q: Are there any common misunderstandings about how this medicine works that official sources clarify?

Yes. Official sources clarify that the medicine decreases only the excessive intestinal hypersecretion (fluid loss) associated with diarrhea. Crucially, it does not affect the body's normal, basal secretion, nor does it modify the duration of intestinal transit.

How should Hidrasec Children be stored and disposed of?

Storage and Disposal Requirements for Hidrasec Children

Hidrasec Children granules for oral suspension must be stored strictly according to the conditions defined in the official regulatory documents to ensure product stability.

Storage Conditions and Child Safety

The medicine must be stored at a temperature not exceeding 30°C. It is mandatory to keep the product protected from moisture, heat, and direct light. The granules should remain in the original sachet and outer carton until the moment of use. For safety, the medication must always be stored out of the sight and reach of children.

Disposal Instructions

Proper management of expired or unused medication is required. The product must not be disposed of via household waste or flushed down the wastewater system (e.g., sink or toilet). Individuals are instructed to consult a pharmacist or local authority for guidance on the correct procedures for pharmaceutical waste disposal.

Hidrasec Children